公开(公告)号：US20220196678A1

公开(公告)日：2022-06-23

申请号：US17432521

申请日：2020-02-21

Applicant: B.R.A.H.M.S. GmbH ,  Linkoping University Hospital

Inventor： Darius Wilson ,  Michelle S. Chew ,  Henrik Andersson

IPC: G01N33/68

Abstract: The invention pertains to a method for the prognosis and/or risk assessment and/or diagnosis of a major adverse cardio- or cerebrovascular event (MACCE) in a patient who underwent gastrointestinal surgery, the method comprising the steps of: i) providing a sample of a bodily fluid from said patient, ii) determining in said sample the level of a biomarker selected from the group consisting of copeptin, troponin and brain natriuretic peptide (BNP), iii) determining at least one additional parameter of said patient, iv) combining the biomarker level determined in step ii) and the additional parameter determined in step iii) into a combined assessment, and v) correlating the combined assessment to said at least one of prognosis, risk assessment and diagnosis of a MACCE in said patient. The invention further pertains to a kit for carrying out the method, a computer and a computer program product comprising computer-executable code being configured to carry out steps iv) and/or v) of the method of the invention.

公开(公告)号：US20210405070A1

公开(公告)日：2021-12-30

申请号：US16972509

申请日：2019-06-06

Applicant: B.R.A.H.M.S GMBH

Inventor： Darius Wilson ,  Aline Pehla ,  Stefan Ebmeyer ,  Frauke Dreyer

IPC: G01N33/74

Abstract: The invention relates to a method for the diagnosis, prognosis, prediction, risk assessment and/or risk stratification of a subsequent trauma-related complication in a polytrauma patient, comprising providing a sample of said patient, wherein the sample is isolated from the patient after the polytrauma, determining a level of pro ADM or fragment(s) thereof in said sample, wherein said level of pro ADM or fragment(s) thereof correlates with the likelihood of a subsequent trauma-related complication

公开(公告)号：US20210293830A1

公开(公告)日：2021-09-23

申请号：US17266243

申请日：2019-08-08

Applicant: B.R.A.H.M.S GmbH ,  Instituto de Investigación Biomédica de Salamanca

Inventor： Darius Wilson ,  Jesús Francisco Bermejo Martin ,  Luis Garcia Ortiz ,  Carmen Herrero Rodriguez

IPC: G01N33/68 ,  G01N33/74

Abstract: The invention relates to a method for therapy guidance, stratification and/or control in a patient with symptoms of an infectious disease, comprising a prognosis of disease progression, the method comprising: providing a sample from said patient, and determining a level of proADM or fragment(s) thereof in said sample, wherein a low risk level of proADM level or fragment(s) thereof in said sample indicates that the patient is not at risk of a disease progression to a condition that requires hospitalization, wherein said low risk level is preferably equal or below 1.2 nmol/l±20%, and/or wherein a high risk level of proADM level or fragment(s) thereof in said sample indicates that the patient is at risk of a disease progression to a condition that requires hospitalization, wherein said high risk level is preferably above 1.2 nmol/l±20%. The invention further relates to a test kit for carrying out the method.

公开(公告)号：US20210109118A1

公开(公告)日：2021-04-15

申请号：US16956046

申请日：2018-12-20

Applicant: B.R.A.H.M.S GmbH

Inventor： Darius WILSON

IPC: G01N33/74

Abstract: The invention relates to a method for antibiotic therapy guidance, stratification and/or control in a patient suspected of having an infection. In particular, the method comprises providing a sample form said patient, determining a level of proADM or fragment(s) thereof in said sample, and wherein the level of proADM or fragment(s) thereof in said sample is indicative of whether an initiation or a change of an antibiotic treatment is required. In a preferred embodiment of the invention, the method comprises additionally determining in a sample from said patient a level of PCT or fragment(s) thereof. Furthermore, the invention also relates to a kit for carrying out the method of the present invention.

公开(公告)号：US10921330B2

公开(公告)日：2021-02-16

申请号：US14966843

申请日：2015-12-11

Applicant: B.R.A.H.M.S GmbH

Inventor： Andreas Bergmann ,  Andrea Sparwaβer ,  Harald Hampel

IPC: A61K49/00 ,  A61K49/16 ,  A61B5/00 ,  G01N33/53 ,  G01N33/74 ,  G01N33/68 ,  G01N33/50 ,  G01N33/557 ,  A61K38/16 ,  C07K16/18 ,  A61K38/23 ,  G01N33/48

Abstract: CSF diagnostic in vitro method for the diagnosis of dementias and neuroinflammatory diseases, in which a determination of the procalcitonin immunoreactivity (PCT immunoreactivity) is carried out in a sample of cerebrospinal fluid (CSF) of a patient who is suffering from a dementia or neuroinflammatory disease or is suspected of suffering from such a disease. Conclusions about the presence, the course, the severity or the success of a treatment of the dementia or neuroinflammatory disease are drawn from a measured PCT immunoreactivity which is above a threshold value typical for healthy individuals.

公开(公告)号：US20200371113A1

公开(公告)日：2020-11-26

申请号：US16636235

申请日：2018-08-06

Applicant: B.R.A.H.M.S GMBH ,  UNIVERSITAT HEIDELBERG

Inventor： Thorsten BRENNER ,  Markus Alexander WEIGAND ,  Florian UHLE ,  Darius Cameron WILSON

IPC: G01N33/68

Abstract: The invention relates to a method for the diagnosis and/or risk stratification of invasive fungal infections (IFI)/invasive fungal diseases (IFD) and in particular associated with sepsis or septic shock, wherein a determination of the marker proadrenomedullin (proADM) or a partial peptide or fragment thereof, in particular midregional proadrenomedullin (MR-proADM), or contained in a marker combination (panel, cluster), is carried out from a patient to be examined. Furthermore, the invention relates to a diagnostic assay and a kit for carrying out the method.

公开(公告)号：US20200319212A1

公开(公告)日：2020-10-08

申请号：US16956330

申请日：2018-12-20

Applicant: B.R.A.H.M.S GMBH

Inventor： Darius WILSON ,  Stefan KIRSCH

IPC: G01N33/74 ,  G01N33/50

Abstract: A method for antibiotic therapy guidance, stratification and/or control in a patient with one or more comorbidities comprising an impaired innate immune response and suspected of having an infection. Also, a method for antibiotic therapy guidance, stratification and/or control in a patient with one or more comorbidities comprising an impaired innate immune response, wherein the comorbidity is preferably selected from the group comprising metabolic disorder (obesity), diabetes, hypertension, renal disease, thrombosis, malignancy or cancer, and suspected of having an infection. In particular, the method comprises providing a sample from said patient and determining a level of PCT or fragment(s) thereof in said sample, wherein the level of PCT or fragment(s) thereof in said sample is indicative of whether an initiation or a change of an antibiotic treatment is required. Furthermore, a kit for carrying out the method of the present invention.

公开(公告)号：US20190224135A1

公开(公告)日：2019-07-25

申请号：US16369966

申请日：2019-03-29

Applicant: B.R.A.H.M.S. GmbH

Inventor： Joachim STRUCK ,  Andreas BERGMANN

IPC: A61K31/00 ,  G01N33/74 ,  G01N33/68

Abstract: Subject of the present invention are assays and in vitro methods for the in vitro diagnosis, prognosis and risk stratification of a patient having a primary, non-infectious disease, whereby the level of Procalcitonin (PCT) in a sample of a body fluid of the patient is indicative for the risk of the patient to contract a further disease or medical condition.

公开(公告)号：US10024872B2

公开(公告)日：2018-07-17

申请号：US14903893

申请日：2014-07-10

Applicant: B.R.A.H.M.S. GMBH

Inventor： Joachim Struck ,  Tim Ziera

IPC: G01N33/573 ,  G01N33/74 ,  C07K16/26 ,  C12N5/12

Abstract: The present invention relates to an immunoassay method for the detection of augurin or a precursor or fragment thereof comprising contacting a sample suspected of comprising augurin or a precursor or fragment thereof with a first and second antibody specific for augurin or a precursor or fragment thereof, wherein said first and second antibodies or antigen-binding fragments or derivatives thereof are specific for epitopes comprised in the sequence spanning amino acids 71 to 107 of pre-augurin according to SEQ ID NO:1.

公开(公告)号：US20170131297A1

公开(公告)日：2017-05-11

申请号：US15412648

申请日：2017-01-23

Applicant: B.R.A.H.M.S GMBH

Inventor： Joachim STRUCK

IPC: G01N33/74 ,  C07K16/26 ,  C12N5/16

CPC classification number: G01N33/74 ,  C07K16/26 ,  C07K2317/34 ,  C12N5/16 ,  G01N2333/5753

Abstract: The present invention relates to an in vitro method for the detection of Procalcitonin or a fragment thereof of at least 20 amino acid residues in length in a biological sample derived from a bodily fluid obtained from a subject, comprising the steps of: (i) contacting said sample with at least two antibodies or functional fragments thereof directed against different epitopes within Procalcitonin, and (ii) qualitatively or quantitatively detecting binding of said at least two antibodies to Procalcitonin or said fragment thereof, wherein binding indicates the presence or concentration of Procalcitonin or said fragment in said sample, wherein at least one antibody or functional fragment thereof is directed against an epitope comprised in the sequence spanning amino acid residues 2 to 52 of Procalcitonin. The invention also pertains to antibodies directed against an N-terminal epitope of Procalcitonin and kits comprising antibodies directed against PCT.